France· FR:65488266
MINJUVI 200 mg, poudre pour solution à diluer pour perfusion
A medicinal product containing tafasitamab, registered in France by INCYTE BIOSCIENCES DISTRIBUTION (PAYS-BAS).
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- TAFASITAMAB
- Manufacturer
- INCYTE BIOSCIENCES DISTRIBUTION (PAYS-BAS)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009550833751 flacon(s) en verre de 200 mg
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tafasitamab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsMinjuvi 200 mg poeder voor concentraat voor oplossing voor infusieIncyte Biosciences Distribution B.V.
- FinlandMINJUVIOrifarm Oy
- United StatesMONJUVIIncyte Corporation
- SwitzerlandMinjuvi 200 mg, poudre pour solution à diluer pour perfusionIncyte Biosciences International Sàrl
- CzechiaMINJUVIIncyte Biosciences Distribution B.V., Amsterdam
- SpainMINJUVI 200 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONIncyte Biosciences Distribution B.V.
- United KingdomMinjuvi 200mg powder for concentrate for solution for infusion vialsIncyte Biosciences UK Ltd
- BelgiumMinjuvi 200 mgIncyte Biosciences Distribution
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Minjuvi
- Liechtenstein · Minjuvi
- Norway · Minjuvi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/31869617-13b3-473c-add7-eb396ca8e5b6 GET /v1/drugs/31869617-13b3-473c-add7-eb396ca8e5b6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "65488266",
"date_amm": "2021-08-26",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/21/1570",
"substance": "TAFASITAMAB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "poudre pour solution à diluer pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about tafasitamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.